Patients taking a typical blood pressure should check the drug after labeling error.
The agency in charge of the fact that the UK pharmaceuticals is safe advised to check the placement number to a person taking the lerkanidipine HCI 20mg tablet of the manufacturer, Recordati Pharmaceuticals.
Those who take the medicine should prevent the expiration date of 01/2028 as a preventive measure, the agency said it should be “urgently”.
The warning comes after the manufacturer informs the intensity of the product printed on the pharmaceutical and medical product regulatory agencies (MHRA).
When the pack is actually 20 mg tablets, the wrong error is limited to one batch.
The correct strength is printed on the top of the box and the blister strip, but the company has issued a recall of placement designated as preventive measures.
Lercanidipine HCI 20mg tablet. PIC: MHRA
Patients who have been prescribed 10mg tablets with the batch number were instructed to call 111 if they could not contact or reach GP or pharmacist immediately.
According to MHRA, patients who cannot tell medical professionals before the next dose are planned, if the tablet is 20mg, and in some cases, in the case of the brake line, the tablet should be snaped in half.
See in detail in Sky News:
Former Lock Dale footballer died at age 36.
Two of the four British were killed by a cable car conflict.
Dr. Alison Cave, the chief safety officer of MHRA, said that patient safety is the “top priority” of the institution.
“We ask patients to check the packaging and follow our advice,” she said.
“Medical professionals like pharmacists should also be returned to suppliers without supplying medicine in the affected batch.”
Patients suspected of experiencing side effects were requested to report through MHRA’s yellow card system.
